Table 4.

Predictive model for post-induction hypotension in patients undergoing transcatheter aortic valve implantation

	aOR	95%CI	P value
(Intercept)	4.960	1.750, 14.00	0.003*
STS risk score ≥6.5%	3.030	0.908, 10.10	0.071
mPG ≥60 mmHg	1.610	0.724, 3.950	0.242
Baseline MAP ≥90 mmHg	0.413	0.193, 0.887	0.023*
Dose of rm for induction (per 1 mg/kg increase)	1.070	0.009, 126.0	0.977
Dose of prop for induction (per 1 mg/kg increase)	3.240	1.320, 7.920	0.010*
Dose of fent for induction (per 1 µg/kg increase)	0.619	0.418, 0.915	0.016*
Dose of remi for induction (per 1 µg/kg/min increase)	0.485	0.137, 1.710	0.261
Dose of keta for induction (per 1 mg/kg increase)	0.163	0.062, 0.430	0.002*

Multivariate logistic regression analyses were performed to develop predictive models for post-induction hypotension in patients who underwent transcatheter aortic valve implantation. No variance inflation factor value was up to 10, indicating no collinearity in the model. The area under the curve was 0.802 (95% CI: 0.732, 0.873)

aOR adjusted odds ratio, CI confidence interval, STS Society of Thoracic Surgeons, mPG mean pressure gradient, MAP mean arterial pressure, Rm remimazolam, Prop propofol, Keta ketamine, Remi remifentanil, Fent fentanyl

^* significant difference